Race Oncology Ltd has released a press release.
Bisantrene Phase 2 AML Trial Successful Concludes
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- RC220 GLP Non-clinical Toxicology Program Successful
- Race Appoints George Clinical for Phase 1 Trial of RC220
- FDA RPD Designation Granted for RC220 Bisantrene
- Bisantrene Highly Active in a Multiple Myeloma Mouse Model
- US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
Later from Racura Oncology
- Race Oncology Board Renewal Update
- Race Discovers Multiple Novel FTO Inhibitor Candidates
- Race Submits Human Ethics for RC220 Phase 1 Trial
- Race Receives $5.25m RD Tax Refund for Financial Year 2024
- Quarterly Activity Report and Appendix 4C
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology